Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRE-515 in Advanced Solid Tumors
NCT05055609Phase 1Recruiting
- Sponsor
- Trethera
- Start
- Sep 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TRE-515 in solid tumor, sponsored by Trethera. Primary endpoints: Number of Participants with Adverse Events (AEs) up to 60 months and Incidence of dose-limiting toxicities at 21 days. Started Sep 2021; status: recruiting.
02
Drugs
TRE-515
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05055609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05055609.